These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 8528978)

  • 21. Circadian rhythms and cancer chemotherapy.
    Focan C
    Pharmacol Ther; 1995; 67(1):1-52. PubMed ID: 7494859
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Modeling and optimization of combined cytostatic and cytotoxic cancer chemotherapy.
    Villasana M; Ochoa G; Aguilar S
    Artif Intell Med; 2010 Nov; 50(3):163-73. PubMed ID: 20620035
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The circadian timing system: a coordinator of life processes: chronobiological investigations. Implications for the rhythmic delivery of cancer therapeutics.
    Lévi FA
    IEEE Eng Med Biol Mag; 2008; 27(1):17-9. PubMed ID: 18270045
    [No Abstract]   [Full Text] [Related]  

  • 24. [Will transfer of cytostatic drug resistance genes increase hematopoiesis resistance in the treatment of malignant tumors?].
    Jelínek J; Fairbairn LJ; Dexter TM; Rafferty JA; Stocking C; Baum C; Ostertag W; Margison GP
    Cas Lek Cesk; 1997 Jan; 136(1):22-6. PubMed ID: 9147848
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [The circadian-timing system: a determinant of drug activity and a target of anticancer treatments].
    Lévi F
    Ann Pharm Fr; 2008 Jun; 66(3):175-84. PubMed ID: 18706346
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Changing patient perceptions of the side effects of cancer chemotherapy.
    Carelle N; Piotto E; Bellanger A; Germanaud J; Thuillier A; Khayat D
    Cancer; 2002 Jul; 95(1):155-63. PubMed ID: 12115329
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Electroporation therapy of solid tumors.
    Hofmann GA; Dev SB; Nanda GS; Rabussay D
    Crit Rev Ther Drug Carrier Syst; 1999; 16(6):523-69. PubMed ID: 10677801
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Rational targeting of Notch signaling in cancer.
    Rizzo P; Osipo C; Foreman K; Golde T; Osborne B; Miele L
    Oncogene; 2008 Sep; 27(38):5124-31. PubMed ID: 18758481
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Antiangiogenic potency of various chemotherapeutic drugs for metronomic chemotherapy.
    Drevs J; Fakler J; Eisele S; Medinger M; Bing G; Esser N; Marmé D; Unger C
    Anticancer Res; 2004; 24(3a):1759-63. PubMed ID: 15274352
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The dynamics of cell proliferation.
    Moxnes JF; Haux J; Hausken K
    Med Hypotheses; 2004; 62(4):556-63. PubMed ID: 15050107
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cancer chronotherapy: principles, applications, and perspectives.
    Mormont MC; Levi F
    Cancer; 2003 Jan; 97(1):155-69. PubMed ID: 12491517
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Nanoparticles for delivery of chemotherapeutic agents to tumors.
    Vijayaraghavalu S; Raghavan D; Labhasetwar V
    Curr Opin Investig Drugs; 2007 Jun; 8(6):477-84. PubMed ID: 17621878
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Principles of drug therapy of malignant tumors: the role of malignant progression in the choice of effective drugs].
    Jeney A; Rosta A
    Orv Hetil; 1999 May; 140(22):1245-9. PubMed ID: 10377736
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Accelerated senescence: an emerging role in tumor cell response to chemotherapy and radiation.
    Gewirtz DA; Holt SE; Elmore LW
    Biochem Pharmacol; 2008 Oct; 76(8):947-57. PubMed ID: 18657518
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Toxic factors limiting the use of anticancer agents.
    Hottendorf GH
    Chemioterapia; 1985 Oct; 4(5):383-7. PubMed ID: 4075433
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Additive effects of TRAIL and paclitaxel on cancer cells: implications for advances in cancer therapy.
    Odoux C; Albers A
    Vitam Horm; 2004; 67():385-407. PubMed ID: 15110187
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Anticancer Drug Development: The Way Forward.
    Connors T
    Oncologist; 1996; 1(3):180-181. PubMed ID: 10387985
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Relevance of circadian cell kinetics in the timing of chemotherapy in animal tumors.
    Focan C
    In Vivo; 1995; 9(6):573-81. PubMed ID: 8726804
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Autologous soluble tumor-associated antigens prevent the toxic side effects of cancer chemotherapy and inhibit the progress of tumorigenesis: case report.
    Ben-Hur H; Zusman R; Zusman I
    Oncol Rep; 2003; 10(6):2059-61. PubMed ID: 14534743
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cancer chronomics I. Origins of timed cancer treatment: early marker rhythm-guided individualized chronochemotherapy.
    Halberg F; Prem K; Halberg F; Norman C; Cornélissen G
    J Exp Ther Oncol; 2006; 6(1):55-61. PubMed ID: 17228525
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.